Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance
An adjuvanted recombinant zoster vaccine (RZV) is licensed for the prevention of herpes zoster. This paper reviews its safety and reactogenicity. A pooled analysis of two pivotal randomized Phase-3 trials (NCT01165177, NCT01165229) in adults ⩾50 years found that more solicited adverse events (AEs) w...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
SAGE Publishing
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/f12022cce94141bd915d1c65071e6be6 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|